Madison Vaccines Announces Expansion Of A Phase 2 Clinical Trial For MVI-816, Its Lead DNA Vaccine For Prostate Cancer
6/23/2014 8:56:52 AM
MADISON, Wisc.--(BUSINESS WIRE)--Madison Vaccines Incorporated (MVI), a clinical stage biopharmaceutical company, today announced enrollment has begun in the expansion of a Phase 2 clinical trial of its lead product candidate MVI-816 (pTVG-HP). The expansion will add 50 patients to the original cohort of 56 patients to produce more robust results. The trial is enrolling non-metastatic prostate cancer patients who have rising PSA after their primary treatment (surgery or radiation), but before patients require androgen deprivation therapy (castration therapy). The trial is seeking clinical evidence that MVI-816 can delay the onset of metastatic disease in these patients. The trial is funded by the company, with patient recruitment currently underway at the University of Wisconsin, and future enrollment anticipated at the University of California San Francisco and at least one other site later this year.
Help employers find you! Check out all the jobs and post your resume.
comments powered by